Gastrin induced autophagy in gastric adenocarcinoma cells by Solum, Guri
i 
 
 
 
 
Gastrin induced autophagy in gastric 
adenocarcinoma cells 
 
Master of Science in Molecular Medicine 
 
Guri Solum, May 2014 
 
 
 
 
 
  
ii 
 
Acknowledgement 
 
This master thesis was part of the study program Masters of Science in Molecular Medicine, 
Faculty of Medicine (DMF) at the Norwegian University of Science and Technology 
(NTNU). The work presented in this thesis was carried out in the Gastroenterology and Cell 
biology research group at the Department of Cancer Research and Molecular Medicine (IKM) 
from August 2013 to May 2014.  
First I would like to thank my supervisor, Professor Liv Thommesen for being of great help 
during the thesis. Thank you for always being enthusiastic, answering my questions and 
sharing your knowledge and your experience.  
I thank my co-supervisor, Ph.D. fellow Shalini Rao, for teaching me techniques in the lab, for 
always taking time to answer my questions, participating in discussions and giving me advice 
during the whole process. I also thank my fellow student Tonje Bjørnetrø for practical help in 
the lab and discussions about my project. You have both greatly contributed to a nice working 
and social environment in the lab.  
Thank to the rest of the Gastroenterology and Cell biology research group, and especially 
Kristin Nørsett, for feedback and a nice working environment.  
Finally I thank Håvard Geithus for proofreading my thesis.  
 
  
 
 
 
Trondheim, May 2014 
 
Guri Solum 
iii 
 
Abstract 
 
The Gastroenterology and Cell biology research group at NTNU studies the role of gastrin in 
gastric cancer. Gastrin is shown to be involved in proliferation, anti-apoptosis, migration, 
invasion and angiogenesis. The role of gastrin in gastric adenocarcinoma is debated, but 
hypergastrinemia is considered to be a risk factor for gastric cancer. Autophagy is a cellular 
degradation process, wherein damaged cytosolic components are engulfed, and the 
components are degraded and recycled. The role of autophagy in cancer is complex since 
autophagy both may promote and inhibit malignancy. In this study it was of interest to 
examine the role of gastrin in autophagy. Two gastric adenocarcinoma cell lines have been 
used during the study.  
We show for the first time that gastrin treatment increases the expression of the autophagic 
markers LC3-II and p62 in AGS-Gr and MKN45 cells. Blocking of the CCK2 receptor 
inhibited the gastrin-mediated increase of LC3-II and p62. Gastrin treatment increased the 
expression of phosphorylated LKB1 (Ser428), AMPK (Thr172) and ULK1 (Ser317, 5), a 
pathway known to induce autophagy. Moreover, gastrin was shown to reduce the apoptotic 
effect mediated by cisplatin in AGS-Gr cells. This survival effect of gastrin was reduced when 
blocking autophagy. This indicates that gastrin-mediated autophagy likely induces protective 
properties in response to cisplatin, and autophagy may be a mechanism of the survival effects 
of gastrin. 
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Abbreviations 
 
AICAR 5-amino-4-imidazolecarboxamide riboside 
AMPK  Adenosine-activated protein kinase 
ATF6  Activating transcription factor 6 
Atg  Autophagy-related genes 
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BSA  Bovine serum albumine 
CCK2   Cholecystokinin 2 
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ER  Endoplasmic reticulum 
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GRP  Gastrin-releasing peptide 
HCQ  Hydroxychloroquine  
IRE1  Inositol-requiring enzyme 1 
Jak/STAT Janus Kinase/Signal Transducer and Activator of Transcription 
LC3  Microtubule-associated protein 1 light chain 3 
LKB1  Liver kinase B1 
MAPK  Mitogen-activated protein kinase 
mTOR  Mammalian target of rapamycin 
PBS  Phosphate buffered saline 
PE  Phosphatidylethanolamine 
PERK  Pancreatic ER kinase (PKR)-like ER kinase 
PI3K  Phosphatidylinositol 3-kinase  
PLC  Phospholipase C  
ROS  Reactive oxygen species 
TBST  Tris-buffered saline Tween 
ULK1  UNC-51-like kinase 1 
UPR  Unfolded protein response 
ZES  Zollinger-Ellinson syndrome  
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1. Introduction 
 
1.1 Gastrin 
 
The peptide hormone gastrin exerts its function as a regulator of gastric acid secretion to 
maintain an appropriate pH value for digestive enzymes. Gastric acid also makes an 
unfavourable environment for microorganisms. Gastrin is shown to have a general trophic 
effect on the gastric mucosa, and regulates growth and differentiation of the stomach [1-3]. 
The stomach is lined by an epithelium that is folded into glands, and contains a diversity of 
cells. Among them are G-cells, D-cells, enterochromaffin-like (ECL) cells, parietal cells, 
mucous-producing pit and neck cells, and stem cells. Stem cells differentiate into the 
specialized cells of the gastric mucosa, and the gastric epithelium is under constant renewal 
[1]. 
Gastric acid is regulated by the interplay between G cells, ECL cell, D cells and parietal cells 
(figure 1.1). Endocrine G-cells have microvilli on their surface that detects dietary amino 
acids and peptides after a meal. In response to a meal, gastrin is synthesized from the G-cells 
and released by exocytosis into the circulation. Gastrin binds to its receptor on the 
neuroendocrine ECL cells in the gastric epithelium, and this binding stimulate release of 
histamine from the ECL cells. Histamine interacts with parietal cells and leads to the release 
of gastric acid by the parietal cells into the lumen of the stomach [1, 4]. Gastric acid secretion 
is regulated by somatostatin and gastrin-releasing peptide (GRP). GRP is a positive regulator 
of gastrin and induces the production of gastrin from the G-cells. However, GRP may also 
induce the release of somatostatin from the D-cell in a negative feedback loop. Somatostatin 
is released by D-cells in response to gastric acid and histamine secretion, and inhibits the 
transcription of gastrin and thus its release from the G cells [1, 2, 4].  
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Figure 1.1: Regulation of gastrin secretion. Gastrin-releasing peptide (GRP) stimulates gastrin-
secretion from the G cell, and gastrin binds to its receptor on the ECL cell and induces secretion of 
histamine. Histamine stimulates the parietal cell to secrete gastric acid. Somatostatin inhibits the 
release of gastrin in response to histamine and acid secretion.  
 
1.2 Gastric cancer 
 
Gastric cancer is the second most common cause of cancer-related death worldwide. Although 
the incidence has decreased over the decades, mortality is still high. Adenocarcinomas 
account for most of malignant gastric cancers [5-7]. Gastric adenocarcinomas are associated 
with chronic Helicobacter pylori (H. pylori) infection, which cause inflammatory cascades 
that may further result in malignancy [8]. H. pylori colonize the mucus layer of the stomach 
and produces urease enzymes. Infection with H. pylori causes reduced secretion of gastric 
acid (achlorhydria) and inhibits the somatostatin negative feedback regulation, leading to 
increased pH. This gives a basic environment that stimulates more production of gastrin, 
leading to hypergastrinemia. Achlorhydria gives a more favourable environment for 
microorganisms, with subsequent infections and inflammation, and further proliferation of H. 
pylori [1, 2].  
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Gastric adenocarcinomas can be divided into two subgroups; a poorly differentiated diffuse 
type, and an intestinal type associated with H. pylori infection [9]. The intestinal type 
develops through pathological stages from chronic active gastritis, atrophic gastritis, via 
metaplasia and dysplasia to a malignant tumour. In the development of gastric 
adenocarcinoma, the epithelial cells of the gastric mucosa are transformed into an intestinal  
cell type [2, 10]. Studies with transgenic INS-GAS mice have shown that hypergastrinemia 
can induce adenocarcinoma in these mice. INS-GAS mice have elevated serum gastrin 
concentrations at young age, followed by increased proliferation of parietal and ECL cells and 
acid hypersecretion. After 20 months the number of parietal and ECL cells decreases and the 
mice becomes achlorhydric, and progress to dysplasia and develop adenocarcinomas [2, 11, 
12]. In INS-GAS mice infected with H. pylori, adenocarcinomas develop after only 6-7 
months, suggesting that H. pylori accelerates the tumorgenesis [13, 14]. In humans 
hypergastrinemia alone is not shown to induce adenocarsinoma, but is regarded as a risk 
factor in combination with H. pylori infection [1, 2]. Gastrin is reported to stimulate 
proliferation in vitro of the human gastric adenocarcinoma cell lines AGS-Gr [15, 16] and 
MKN45 [17], the rat pancreatic adenocarcinoma cell line AR42J [18-20], and in the human 
colon adenocarcinoma cell line HT-29 [21, 22]. In AGS-Gr cells, gastrin is also shown to 
induce migration and invasion [23].    
Gastrin is shown to stimulate the proliferation of ECL cells in the stomach [2, 24]. 
Hypergastrinemia is associated with the development of ECL-omas, and hypergastrinemia has 
been shown to induce ECL-omas in rats (reviewed in [1, 2]). In the human disease known as 
Zollinger-Ellinson syndrome (ZES), in which gastrin-producing tumours (gastrinomas) cause 
hypergastrinemia, ECL hyperplasi and thicker gastric mucosa has been observed [1, 2]. 
However, in a study where biopsies from 106 patients with sporadic ZES were examined, 
99% had developed ECL hyperplasi, 7% dysplasia, but none had developed carcinoids [25], 
indicating that results from animal models are not directly applicable to humans. 
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1.3 Gastrin-mediated signalling and cellular processes 
 
Cells are dependent on the communication with other cells and their environment.  External 
signals (hormones, cytokines, and growth factors) mediate responses in cells through a signal 
transduction cascade. Ligand binding to a receptor causes a conformational change in the 
receptor, and intracellular mediators and second messengers are activated. Signals can be 
transduced as phosphorylation cascades mediated by kinases. The cascade eventually results 
in activation of transcription factors and altered gene expression [26]. G-protein coupled 
receptors are the most abundant plasma membrane receptors, and are involved in cellular 
processes like proliferation, differentiation and migration [27]. Gastrin binds to and signals 
through the G-protein-coupled cholecystokinin 2 receptor (CCK2 receptor) located among 
others on ECL and parietal cells in the stomach [4, 28].  
Several signalling pathways, including MAPK, PI3K/Akt, PLC-γ and Jak/Stat, are activated 
by the CCK2 receptor. These signalling pathways are known to be involved in proliferation, 
differentiation, adhesion, migration, invasion, angiogenesis and apoptosis (figure 1.2) 
(reviewed in [1, 28]). Deregulation of these cellular processes is crucial in development of 
cancer. In gastric cancer cell model systems, gastrin is reported to stimulate expression of 
genes involved in proliferation and anti-apoptosis via the MEK/ERK and PI3K/Akt pathway, 
and both to induce and inhibit cell proliferation [15, 28-31]. Gastrin is also known to be 
involved in migration and invasion (reviewed in [1, 28]).   
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Figure 1.2: Overview of gastrin-mediated biological processes . Gastrin activates signalling 
pathways through the CCK2 receptor which may induce cell proliferation, migration, adhesion, 
invasion, anti-apoptosis and angiogenesis. Modified from Watson et al. [1].  
 
 
1.4 Autophagy 
 
Autophagy is an intracellular metabolic degradation system which maintains cellular 
homeostasis by engulfing damaged cytosolic components, degrading and recycling them. 
Some level of basal autophagy is needed for turnover of cytosolic components, but autophagy 
can also be induced in response to cellular stress such as nutrient deprivation, pathogen 
infection and hypoxia [32]. In the initial stage of autophagy, damaged components are 
engulfed by a double membrane called a phagophore, which elongates, encloses and matures 
into an autophagosome (figure 1.3). These steps are commonly referred to as initiation, 
nucleation, and elongation. The autophagosome eventually fuses with a lysosome, and the 
acidic environment of the lysosome, containing hydrolytic enzymes, degrades the cytosolic 
components. The understanding of autophagy on a molecular level started with the discovery 
of the autophagy-related genes (Atg) in yeast, and later the mammalian homologs. The 
finding of Atg genes in yeast and homologs in higher eukaryotes suggest that autophagy is 
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highly conserved through evolution. Deregulation of autophagy is linked to several 
pathological conditions, like infections, neurodegeneration and cancer (reviewed in [32, 33]).   
 
 
Figure 1.3: Formation of autophagosomes . Damaged cytosolic components is engulfed by a 
phagophore which elongates and matures into an autophagosome. The autophagosome fuses with a 
lysosome, which lead to the degradation and recycling of cytosolic components. Modified from 
Nakahira et al. [34].  
 
 
1.5 Signalling pathways involved in autophagy 
 
Autophagy is initiated under nutrient starvation, and is suppressed under nutrient-rich 
conditions. Autophagy is regulated by adenosine monophosphate-activated protein kinase 
(AMPK) and the mammalian target of rapamycin (mTOR), which serve as nutrient and 
energy sensors in the cells (figure 1.4). The ULK1 complex is a key modulator of autophagy 
and is required for initiation of autophagy and formation of the phagophore. Under nutrient 
deprivation, activated AMPK (phosphorylated at Thr172) activates ULK1 directly through 
phosphorylation at multiple residues, including Ser317 and Ser555, and indirectly by 
phosphorylation of raptor in the mTOR complex, which inhibits mTOR activity [35, 36]. 
Under nutrient-rich conditions, mTOR is activated via PI3K/Akt and MAPK/ERK pathways, 
and phosphorylates ULK1 (Ser757) to suppress autophagy [36, 37]. Activated LKB1 
(phosphorylated at Ser428), a serine/threonine kinase upstream of AMPK, activates AMPK 
by phosphorylation (Thr172) (figure 1.4) [38].   
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Figure 1.4: Regulation of autophagy. When deprived of nutrients, AMPK phosphorylates ULK1 at 
several residues to initiate autophagy. LKB1 is an activator of AMPK. mTOR phosphorylates ULK1 
in nutrient-rich conditions, thus inhibiting autophagy initiation.  
 
 
The class III phosphatidylinositol 3-kinase (PI3K) complex is required for the recruitment of 
Atg-proteins involved in nucleation, elongation and maturation of the autophagosome (figure 
1.5). The PI3K complex consists of multiple proteins, including Beclin 1. Under normal 
nutrient-rich conditions, Beclin 1 is bound to Bcl-2, a protein known to be involved in anti-
apoptosis. Under nutrient starvation, Bcl-2 dissociates from Beclin 1, which may induce 
autophagy [32]. For maturation into an autophagosome, the Atg12-Atg5-Atg16L complex and 
lipidation of LC3 is required. The Atg12-Atg5-Atg16L complex is involved in recruiting 
LC3-I to the phagophore membrane for lipidation. LC3 is cleaved by Atg5 to form the 
cytosolic form LC3-I. LC3-I is then conjugated to phosphatidylethanolamine (PE) to form the 
lipidated LC3-II, a reaction requiring both Atg7 and Atg3. LC3-II is found on the mature 
autophagosome, and when the autophagosome fuses with the lysosome, LC3-II is degraded. 
Since LC3-II is located on the autophagosome, it is commonly used as a marker for 
autophagy [32, 33, 37, 39]. When using lysosomal inhibitors (Baf and HCQ) that prevent the 
fusion of autophagosomes with lysosomes, it has been shown that LC3-II accumulates [40, 
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41]. Another protein used as an autophagic marker is p62, which is involved in degradation of 
ubiquitiniated proteins, and linking of these proteins to the autophagosome. p62 binds to LC3-
II on the autophagosome and is degraded by autophagy  [33, 42, 43].  
 
 
 
Figure 1.5: Overview of signalling and regulation of autophagy. Autophagy is shown to be 
regulated by AMPK and mTOR. The PI3K class III complex is required for recruiting Atg-proteins 
involved in forming the autophagosome. The Atg16L-Atg12-Atg5 complex and LC3-II is required for 
elongation and maturation of the phagophore. LC3 is cleaved by Atg4 to LC3-I which is conjugated 
with PE to form the lipidated form LC3-II. p62 is found on the autophagosome membrane and is 
degraded by autophagy. LC3-II and p62 accumulates when autophagy is inhibited. Modified from Cell 
signalling technology’s website [44]. 
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1.6 Autophagy and ER-stress 
 
Physiological or pathological conditions may cause an unbalance in the protein folding 
capacity of the endoplasmic reticulum (ER), referred to as ER stress. If the chaperons that are 
in charge of correct folding of proteins exceed their capacity, misfolded, unfolded or damaged 
proteins may accumulate. This initiates the unfolded protein response (UPR) that aims to cope 
with the stress and restore the protein synthesis. The UPR is regulated by three ER stress 
sensors; pancreatic ER kinase (PKR)-like ER kinase (PERK), activating transcription factor 6 
(ATF6), and inositol-requiring enzyme 1 (IRE1). When activated, the proteins translocate to 
the nucleus where they regulate the ER capacity [45-47].  
Tumours may suffer from ER stress and one way to cope with this is induction of autophagy 
to maintain ER homeostasis and preventing cell death. It has been shown that PERK, IRE1 
and ATF6 can interact with proteins in the autophagy pathway, and proteins downstream of 
PERK, IRE1 and ATF6 can induce autophagy (reviewed in [46, 47]). It has previously been 
shown by the Gastroenterology and Cell biology group at NTNU that gastrin treatment 
induces genes involved in ER stress and UPR in the pancreatic adenocarcinoma cell line 
AR42J [30].  
 
1.7 Autophagy in cancer and apoptosis 
 
Autophagy in cancer is often referred to as a double-edged sword – it can both supress and 
promote tumour survival [48]. In early stages of cancer development, autophagy is commonly 
suppressed, but is up-regulated in later stages (reviewed in [49]). In the central areas of a 
tumour the blood supply is often inadequate, and tumour cells may suffer from hypoxia, 
starvation and metabolic stress. Initiation of autophagy may help tumour cells to handle this 
stress. Tumour cells can enter a period of dormancy in which they shrink in size, suppress 
their motility and stop proliferating. During this dormancy state, autophagy contributes to 
survival until normal conditions are re-established [48, 50]. Even though autophagy may help 
tumour cells to survive stressful situations, defective autophagy may also be of advantage for 
tumour cells. Damage in cells can lead to the production of reactive oxygen species (ROS), 
and thus cause DNA damage. Defective autophagy can cause accumulation of DNA damage, 
and further genetic instability for the tumour cells [50, 51]. Defective autophagy may also 
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induce necrotic cell death, tissue damage and an inflammation response that favours further 
tumour progression [50]. 
Autophagy may also act in a tumour-suppressing manner. Over-stimulation of autophagy can 
cause a rate of self-digestion that exceeds the capacity of the cells, resulting in apoptosis. 
Induction of DNA damage can be counteracted by autophagy and thus prevent genetic 
instability in tumour cells [48, 52]. Autophagy can suppress tumour development by limiting 
necrotic cell death and thus limit inflammation [48].  
Autophagic cell death is morphologically characterized by autophagic vacuoles in the cytosol 
of the dying cell. In apoptotic cell death the end product is cellular destruction mediated by 
caspases, and is morphologically characterized by fragmentation, shrinkage, and nuclear 
condensation [53, 54]. The interplay between apoptosis and autophagy in cancer is complex. 
Autophagy can help tumour cells to escape apoptotic cell death under stress, and this have 
been further established by pharmacological inhibition of autophagy, which induced apoptosis 
[50, 51, 55, 56]. The stage of autophagy inhibition affects the phenotype of the cell death. 
With inhibition at an early stage the morphology resembles to an apoptotic cell death. By 
inhibiting the fusion of autophagosomes with lysosomes, accumulation of autophagosomes is 
seen prior to apoptotic cell death, giving a mixed phenotype [51, 55].  
Several proteins, including Beclin 1, are known to interact with both apoptosis and autophagy 
(reviewed in [57]). Anti-apoptotic proteins of the BCL-2 family interact with Beclin 1, and 
this interaction inhibits initiation of autophagy. Pro-apoptotic BH3-only proteins can disrupt 
this interaction, and allows Beclin 1 to induce autophagy by interacting with the PI3K class 
III complex [57, 58]. Accumulation of p62 due to defective autophagy is shown to produce 
ROS and DNA damage, which can lead to apoptosis [59]. Induction of apoptosis leads to 
activation of caspases which can inhibit autophagy by cleavage of proteins essential for 
autophagy. Cleaved fragments from Beclin 1 can gain pro-apoptotic properties by inducing 
the release of cytochrome c from the mitochondria [57, 60].  
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1.8 Aim of study 
 
The Gastroenterology and Cell biology group at NTNU is interested in the role of gastrin in 
adenocarcinoma cell systems, and have previously shown that gastrin is involved in 
endoplasmic reticulum (ER) stress responses. The possible role of gastrin in regulation of 
autophagy was therefore of interest. The understanding of mechanisms regulating autophagy 
is of great impact in cancer therapy strategies. Today, little is known about autophagy in 
gastric cancer and the possible role of gastrin. The aim of the study was:  
 Characterize the role of gastrin in autophagy in gastric adenocarcinoma cell lines 
o Examine whether gastrin regulate autophagy in gastric adenocarcinoma cells 
o Characterize signalling pathways that are involved in gastrin mediated-
autophagy 
o Optimizing Western blot for detection of phosphorylated kinases involved in 
autophagy 
o Characterize the cellular consequence of gastrin-mediated autophagy 
 
 
 
 
.   
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2. Materials and method 
 
2.1 Cell culture and experimental setup 
 
The human gastric adenocarcinoma cell lines AGS-Gr and MKN45 have been used during the 
course of this study. AGS-Gr cells are transfected AGS cells (ATTC), which originate from a 
tumour in the epithelium of the stomach. AGS-Gr cells are stably transfected with the CCK2 
receptor, and was given as a gift from Professor Andrea Varro at the University of Liverpool, 
England. MKN45 cells expressing the CCK2 receptor endogenously, were given as a gift 
from Professor Sue Watson at the Department of Surgery, Queens Medical Centre at the 
University Hospital, Nottingham.  
The AGS-Gr cells were cultivated in HAM’s F12 medium (Gibco, Carlsbad, CA) and 
MKN45 cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco). 
Both cell lines were supplemented with 10% FCS (Sigma, St. Louis, MO), 100 U/ml 
penicillin, 100 µg/ml streptomycin (Gibco) and 1 µg/ml fungizone (Gibco). The cells were 
incubated at 37°C in a humidified environment containing 5% CO2.  During splitting, cells 
were detached from the surface by trypsin with 0.25% EDTA (Gibco).  
For Western blot analysis, 0.3x106 AGS-Gr and MKN45 cells were seeded into 6 well plates 
or 1.5x106 cells were seeded into 100 x 20 mm petri dishes for detection of LC3-II and p62.  
For the detection of phosphorylated proteins, 1.5x106 cells were seeded into 100 x 20 mm 
petri dishes. Cells were allowed to grow for one day. The cells were then treated with gastrin 
(10 nM) (G17, Sigma) in the presence of Bafolimycin A1 (Baf) (100 nM) (Sigma) for 2, 4 and 
8 hours, both in serum-free F12/DMEM and HANKS balanced salt solution (Sigma). In the 
experiments where the CCK2 receptor was blocked, cells were treated with YM022 (Sigma) 
(100 nM) overnight before gastrin was added for 4 hours. For phosphorylated proteins, the 
cells were serum-starved for 14-20 hours and treated with 10 nM gastrin for 5, 10, 15, 30 and 
60 minutes. As a positive control for phosphorylation of LKB1 and AMPK, cells were treated 
two hours with AICAR (0.5 nM). As a positive control for ULK1 cells were treated with 
FCCP (100 nM) for two hours.  
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2.2 Western blot  
 
Cells were harvested after the stimulation, centrifuged (430 x g) for 8 minutes, and the cell 
pellet was re-suspended in PBS (Thermo Scientific, Rockford, IL) with 10% FCS. The cell 
suspension was centrifuged (430 x g) for 8 minutes, and 2x volume of the cell pellet of urea 
lysis buffer (Sigma) was added (Appendix 1). The samples were mixed several times, before a 
final centrifugation (16 000 x g) for 16 minutes. The supernatant was transferred into new 
Eppendorf tubes, and stored at- 80°C.  
For protein estimation, the Bio-Rad protein assay dye reagent (BIORAD Laboratories, 
Hercules, CA) was used (diluted 1:5 in H2O). Protein lysate (1 µl) was added the diluted Bio-
Rad solution (1 ml). The absorbance in the samples was measured at 595 nm. Each sample 
was measured in triplicates. A standard curve was generated by use of BSA, and used for 
calculating the protein concentrations.  
The samples were mixed with loading dye (LDS) (5 µl) (Invitrogen, Carlsbad, CA) and sterile 
water to add up the same volume for each sample. The proteins were then denatured by 
heating the samples (70ºC) for 10 minutes.  For detection of LC3-II and p62, 35 µg protein 
was loaded, and for the CCK2 receptor, phosphorylated LKB1, AMPK and ULK1, 60 µg 
protein was loaded onto the gel. For further specifications, see table 2.1. The prepared protein 
sample, MagicMark XP Western Protein standard (2µl) (Invitrogen) and Kaleidoscope 
precision plus protein standard (4µl) (BIORAD) was separated on a Bis-Tris NuPAGE gel 
(Invitrogen) with NuPAGE MOPS SDS Running buffer (Novex, Carlsbad, CA). The 
membrane was activated in methanol and washed in 1X (Appendix 1). The proteins were 
transferred to a PVDF Immobilon-p membrane (Millipore, Billerica, MA) with NuPAGE 
MOPS Transfer buffer (Novex) (Appendix 1). To control that the transfer had been successful 
the membranes was activated in methanol and stained with Ponceau (Sigma) (Appendix 1) to 
visualize the bands. The membranes were blocked in 5 % milk (Nestlé, Vevey, Switzerland), 
Odyssey blocking buffer (LI-COR, Nebraska, US)) or 5 % BSA (Sigma). For specification of 
the antibodies, see table 2.2. Primary antibody was added and incubated in room temperature 
or overnight at 4°C. The membrane was washed in TBST after incubation, before secondary 
antibody was added and incubated in room temperature. The membrane was washed in TBST 
when using horse-radish peroxidase (HRP)-probed antibodies, and in TBS when using 
fluorescent secondary antibodies. SuperSignal (Thermo Scientific) was applied for 40 seconds 
to 5 minutes to detect HRP activity from HRP-probed antibodies, and the blot was imaged by 
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Odyssey FC (LI-COR). When the membrane was probed with fluorescent secondary 
antibody, the incubation and wash was performed in the dark, and the membrane was dried in 
darkness for 2-3 hours before developing. The membrane was imaged with Odyssey (LI-
COR). Bands were normalised to β-Actin or GAPDH, and blots were quantified by use of 
Image Studio 3.1 software.  
 
Table 2.1: Western blot specifications.  
Protein detected Running Transfer Blocking 
CCK2 receptor 200 V, 75 minutes, room 
temperature, 10 % gel 
30 V, 80 minutes, room 
temperature 
Overnight in 5 % milk 
LC3-II and p62 200 V, 75 minutes, room 
temperature, 12 % gel 
30 V, 80 minutes, room 
temperature 
2 hours in 5 % milk 
Phosphorylated proteins 200 V, 40 minutes and 
120 V, 80 minutes on ice 
10 or 4-12 % gel. 
30 V, 80 minutes, room 
temperature or 
30 V, 130 minutes on ice 
5% milk, 5 % BSA or 
Odyssey blocking 
buffer 
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Table 2.2: Antibodies used in Western blot. 
Protein detected Antibody Company Dilution Molecular weight 
CCK2 receptor Anti-CCK2R 
Mouse polyclonal 
Abcam 1:1000 48 kDa 
LC3-II LC3B antibody 
Rabbit 
Cell signalling 
technology  
1:1000  14 kDa 
LC3-II LC3B (D11) XP 
Rabbit IgG 
Cell signalling 
technology  
1:1000  14 kDa 
p62 p62  
Guinea pig polyclonal 
Progen Biotechnik  1:1000  62 kDa 
ULK1 (total) ULK1  
Rabbit IgG 
Cell signalling 
technology  
 
1:1000 
 
150 kDa 
pULK1 (Ser317) Phospho-ULK1 (Ser317) 
Rabbit IgG 
Cell signalling 
technology  
 
1:1000/ 
1:500  
 
140 kDa 
pULK1 (Ser555) Phospho-ULK1 (Ser555) 
Rabbit 
Cell signalling 
technology  
 
1:1000  
 
140 kDa 
AMPKα AMPKα 
Rabbit 
Cell signalling 
technology  
 
1:1000 62 kDa 
pAMPK Phospho-AMPKα 
(Thr172) 
Rabbit mAb 
Cell signalling 
technology 
 
1:1000  
 
62 kDa 
LKB1 LKB1  
Rabbit IgG 
Cell signalling 
technology 
 
1:1000 54 kDa 
pLKB1 
(Ser428) 
Phospho-LKB1 (Ser428)  
Rabbit IgG 
Cell signalling 
technology 
 
1:1000 54 kDa 
β-Actin 
(Loading ctrl) 
Anti-beta Actin 
Mouse monoclonal 
Abcam 
 
1:5000 42 kDa 
GAPDH 
(Loading ctrl) 
Anti-GAPDH  
mouse monoclonal 
Abcam 1:5000 
 
40 kDa 
Anti-Rabbit Secondary antibody 
Goat anti-rabbit 
Thermo Scientific 1:5000  
 
 
 
Anti-mouse Secondary antibody 
Polyclonal Goat anti-
mouse 
DAKO 1:5000  
Anti-Guinea pig 
(Fluorescent) 
Secondary antibody 
Donkey anti-guinea pig 
LI-COR  1:5000 
 
 
Anti-mouse 
(Fluorescent) 
Secondary antibody 
Goat anti-mouse 
LI-COR  1:20 000 
 
 
Anti-Rabbit  
(Fluorescent) 
Secondary antibody 
Goat anti-rabbit 
LI-COR  1:5000 
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2.3 Confocal microscopy 
 
10 000 cells per well was seeded in a chambered coverglass, and the cells were left overnight. 
The cells were then fixed with 4 % paraformaldehyde (Merck, Darmstadt, Germany), and left 
for 10 minutes. The liquid was removed and cells were washed once with PBS. Cold 
methanol (-20°C) was added for 10 minutes, and the wells were placed on ice. The cells were 
washed once with PBS. For blocking, 3 % goat serum (Gibco) in PBS was added, and the 
cells were left in blocking overnight at 4°C. The blocking solution was removed, and primary 
antibody, diluted in 1 % goat serum, was added and left for one hour on a shaker. The cells 
were then washed with PBS for 3x10 minutes in room temperature. Secondary antibody was 
diluted in 1% goat serum, and was left for one hour on a shaker. The cells were washed in 
PBS, 4x10 minutes. The cells were protected from light and stored in PBS at 4°C until images 
were taken. Zeiss LSM 510 META microscope was used to capture the images. The 488 
channel (495 nm, green) was used for detection of LC3-II and the 647 channel (650 nm, red) 
for p62. Specifications about the antibodies used are shown in table 2.3: 
Table 2.3: Antibodies used for immunocytochemistry. 
Protein detected Primary antibody Secondary antibody 
p62 Guinea pig polyclonal (1:2000) 
Progen Biotechnik 
Goat Anti- guinea pig (1:5000) 
Progen Biotechnik 
LC3-II Rabbit (1:2000) 
Cell signalling technology 
Goat Anti-rabbit (1:5000) 
Cell signalling technology 
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2.4 XTT assay 
 
XTT assay was performed by using TACS XTT Cell proliferation assay kit (Trevigen, 
Gaithersburg, MD). XTT working solution was made by mixing XTT activator (100 µl) and 
XTT reagent (5 ml) from the kit. 10 000 cells per well were seeded into flat bottom 96 well 
plates and left overnight. The cells were then serum-starved and stimulated with gastrin 
(10nM) for 2 hours, before cisplatin (Merck) was added. Following cisplatin treatment, the 
cells were left for different time points and the XTT working solution (50 µl) was added and 
left for 2 hours before the absorbance was read with iMark Microplate Reader (BIORAD) at 
dual wavelength; 490 nm and 620 nm. In experiments with hydroxy-chloroquine (HCQ) 
(Sigma), HCQ (10 μM) was added 12 and 24 hours after cisplatin and the absorbance was 
measured after 36 and 48 hours of cisplatin stimulation.   
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3. Results 
 
3.1 CCK2 receptor expression  
 
The model system used in this study includes the gastric adenocarcinoma cell lines AGS-Gr 
and MKN45. Gastrin has been shown to induce the expression of the CCK2 receptor in AGS-
Gr cells [61], AR42J [62] and the gastric KATOIII cells [63]. There are only few, and 
relatively old studies about the expression of the CCK2 receptor in MKN45 [64, 65], and 
examining the expression of the CCK2 receptor in these cells was therefore of interest. 
MKN45 cells were serum-starved and treated with gastrin for 2, 4, 8 and 16 hours. The results 
show that the CCK2 receptor is expressed in MKN45 cells, and further show a small increase 
in protein levels after gastrin-stimulation (figure 3.1B). HEK293 cells were included as a 
negative control in this experiment. AGS-Gr is stably transfected with the CCK2 receptor 
[66], and expression of the CCK2 receptor in AGS-Gr have previously been shown by using 
immunocytochemistry (figure 3.1A). However, AGS-Gr cells showed low expression of the 
CCK2 receptor (figure 3.1B). This may be caused by the antibody used for immunoblotting.   
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Figure 3.1: CCK2 receptor expression. A) Cells were fixed and stained for the CCK2 receptor with 
an antibody from Abbiotech. The cells were co-stained using DRAQ5 (experiment performed by Ph.D 
fellow Shalini Rao).  B) Cells were treated with gastrin (10 nM). Protein levels of the CCK2 receptor 
was detected by Western blot, using an antibody from Abcam. The results in B) are representative of 
two biological replicates.  
 
 
3.2 Gastrin mediated induction of the autophagic markers LC3-II and p62  
 
To determine whether gastrin affects autophagy in gastric adenocarcinoma cells lines, the 
levels of the autophagic markers LC3-II and p62 were examined by Western blot. Cells were 
treated with gastrin in the presence of the lysosomal inhibitor Bafilomycin A1 (Baf), and 
simultaneously serum-starved in F12/DMEM or amino acid-starved in HANKS. Since 
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HANKS media contain no amino acids we expected starvation in HANKS to induce higher 
levels of autophagy. Baf prevents the fusion of the autophagosome and the lysosome, 
resulting in accumulation of LC3-II and p62. If gastrin induces autophagy, we expected that 
treatment with gastrin in the presence of Baf would result in higher increase in protein levels 
of LC3-II and p62 than treatment with Baf alone. The results show that LC3-II levels increase 
after 4 and 8 hours of gastrin treatment in the presence of Baf compared to Baf alone in AGS-
Gr cells cultivated in F12 (figure 3.2). The protein level of p62 also increases after 4 and 8 
hours of treatment, but the increase is not as pronounced as for LC3-II (figure 3.2). The level 
of LC3-II increased after 2 and 8 hours of gastrin treatment in the presence of Baf, while the 
level of p62 increased after 2 and 4 hours in cells cultivated in HANKS (figure 3.3). These 
results indicate that gastrin increases the protein levels of the autophagic markers LC3-II and 
p62 in AGS-Gr cells.   
 
Figure 3.2: Expression of LC3-II and p62 in AGS-Gr cells cultivated in F12. Cells were serum-
starved and simultaneously treated with gastrin (10 nM). The results shown are representative from 
one of three independent experiments.  
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Figure 3.3: Expression of LC3-II and p62 in AGS-Gr cells cultivated in HANKS. Cells were 
amino acid-starved and simultaneously treated with gastrin (10 nM). The results shown are from one 
experiment.  
 
Further, we examined the expression of LC3-II and p62 in MKN45 cells. We found that 
cultivation in DMEM increased the expression of LC3-II after 4 hours of gastrin treatment in 
presence of Baf compared to Baf alone (figure 3.4). Increase in p62 levels were observed after 
2 and 4 hours of treatment. When cultivating cells in HANKS, the gastrin-induced increase of 
LC3-II was not very pronounced (figure 3.5). Gastrin did not enhance p62 protein levels in 
cells starved in HANKS. Taken together, these results show that gastrin increases protein 
levels of LC3-II and p62 in MKN45 cells cultivated in DMEM, indicating a role of gastrin in 
autophagy. However, gastrin did not increase autophagy further when cultivating cells in 
HANKS.  
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Figure 3.4: Expression of LC3-II and p62 in MKN45 cells  cultivated in DMEM. Cells were 
serum-starved and simultaneously treated with gastrin (10 nM). The results shown are representative 
from one of three independent experiments.  
 
 
Figure 3.5: Expression of LC3-II and p62 in MKN45 cells  cultivated in HANKS. Cells were 
amino acid-starved and simultaneously treated with gastrin (10 nM). The results shown are from one 
experiment. 
23 
 
3.3 Detection of gastrin induced LC3-II and p62 by use of immunocytochemistry 
 
It was further of interest to assess LC3-II and p62 by immunocytochemistry. MKN45 were 
treated with gastrin in the presence of Baf for 8 hours, and cultivated in both DMEM and 
HANKS media. The staining was visualized using the imaging technique confocal 
microscopy. Gastrin treatment resulted in increased expression of LC3-II and p62 when cells 
were cultivated in DMEM (figure 3.6A). In cells cultivated in HANKS media, no clear 
enhancement of LC3-II and p62 levels were observed (figure 3.6B). Taken together, these 
results are congruent with the Western blot results, and suggest a role of gastrin induced 
autophagy in gastric adenocarcinoma cells.  
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Figure 3.6: Staining of LC3-II and p62 in MKN45. Cells were starved and simultaneously treated 
with gastrin (10nM) for 8 hours and then stained for p62 and LC3-II. A) Cells cultivated in DMEM.                  
B) Cells cultivated in HANKS.  
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3.4 Inhibition of gastrin mediated autophagy 
 
The results so far showed that gastrin induces the autophagic markers LC3-II and p62 in 
AGS-Gr and MKN45 cells. Next we wanted to confirm whether this induction actually was 
mediated through the CCK2 receptor. We found recently that the CCK2 receptor antagonist 
YM022 reduced gastrin-mediated migration in AGS-Gr and MKN45 cells (manuscript in 
progress). YM022 was therefore added to see if blocking the CCK2 receptor would influence 
gastrin-induced LC3-II and p62 levels.  
We observed that the presence of CCK2 receptor antagonist reduced the levels of LC3-II and 
p62 in AGS-Gr cells (figure 3.7A). Similar results were observed in MKN45 cells (figure 
3.7B), indicating that the effect of gastrin was mediated via the CCK2 receptor.  
Notably, pre-treatment with YM022 showed an increase in LC3-II and p62 levels in 
unstimulated MKN45 cells, indicating an off-target effect of YM022. Thus, the role of the 
CCK2 receptor was examined with siRNA, which showed similar results as with the YM022 
inhibitor experiments (data not shown). Taken together, these results indicate that gastrin 
treatment causes an increase in protein levels of LC3-II and p62, and that blocking or knock 
down of the CCK2 receptor inhibits gastrin mediated increase of LC3-II and p62 in AGS-Gr 
and MKN45 cells.  
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Figure 3.7: The CCK2 receptor antagonist YM022 inhibits gastrin mediated autophagy. Cells 
were treated with YM022 (100 nM) overnight, and then treated with gastrin (10 nM) for 4 hours.      
A) AGS-Gr cells. B)  MKN45 cells. The reulsts shown are representative from one of three 
independent experiments. 
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3.5 Gastrin mediated phosphorylation of LKB1, AMPK and ULK1 
 
Since our results suggest that gastrin increases autophagy in AGS-Gr and MKN45 cells, we 
wanted to unravel signalling pathways involved in gastrin induced autophagy. The kinase 
LKB1 is known to phosphorylate and activate the kinase. AMPK is further shown to 
phosphorylate and activate ULK1 to initiate autophagy. Therefore we wanted to examine 
whether gastrin mediated activation of the LKB1 – AMPK – ULK1 pathway. MKN45 and 
AGS-Gr cells were serum-starved and treated with gastrin for 5-60 minutes. The 
phosphorylation of LKB1 (Ser428), AMPK (Thr172), and ULK1 (Ser317, Ser555) was then 
examined by Western blot.  AICAR is shown to induce phosphorylation of both LKB1 and 
AMPK [38], and was included as a positive control for phosphorylated LKB1 and AMPK. As 
a positive control for ULK1, cells were treated with FCCP, shown to induce ULK1 [67].  
Our results showed that the level of phosphorylated LKB1 increased upon gastrin treatment 
with a decline after 60 minutes (figure 3.8). Phosphorylated AMPK seemed to peak after 10 
minutes of gastrin treatment in AGS-Gr cells (figure 3.8) and the levels were still elevated 
after 60 minutes compared to the unstimulated cells. These results indicate that gastrin 
stimulation increases the phosphorylation of LKB1 (Ser428) and AMPK (Thr172) in AGS-Gr 
cells.  
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Figure 3.8: Gastrin-induced phosphorylation of LKB1 and AMPK in AGS-Gr. Cells were serum-
starved and treated with gastrin (10 nM). Phosphorylated LKB1 (Ser428) and AMPK (Thr172) were 
detected by Western blot. Results are representative of two (pLKB1) and three (pAMPK) independent 
experiments.  
  
Next we examined whether gastrin phosphorylated the same kinases in MKN45 cells. We 
found that he level of phosphorylated LKB1 seems to be increased after 10 minutes (figure 
3.9). The level of phosphorylated AMPK increased after 10 minutes and was still increased 
compared to unstimulated cells after 60 minutes (figure 3.9). These results indicate that 
gastrin treatment induces phosphorylation of LKB1 (Ser428) and AMPK (Thr172) also in 
MKN45 cells, but the induction is not as pronounced as in AGS-Gr cells.  
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Figure 3.9: Detection of phosphorylated LKB1 and AMPK in MKN45. Cells were serum-starved 
and stimulated with gastrin (10 nM). Phosphorylated LKB1 (Ser428) and AMPK (Thr172) were 
detected by Western blot. Results are representative of two (LKB1) and three (AMPK) independent 
experiments.  
 
 
3.5.1 Optimizing the method for detection of phosphorylated ULK1 
 
When detecting phosphorylated ULK1, several problems were encountered in AGS-Gr and 
MKN45 cells. Initially, gastrin induced phosphorylation of ULK1 (Ser317) was examined in 
both cell lines. The membrane was blocked 2 hours in 5% BSA. This experimental setup was 
not very successful as unspecific bindings occurred and the bands were poorly separated (data 
not shown). To improve the method, the incubation with blocking buffer (5% BSA) was 
performed overnight at 4ºC, but this did not mitigate the problem of unspecific bindings. The 
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next step was therefore to change the blocking solution. Two new blocking solutions were 
used; 5% milk and Odyssey blocking buffer, but neither reduced the unspecific bindings. 
When detecting phosphorylated ULK1 (Ser317), two bands between 120 and 220 kDa was 
detected (figure 3.10A). Phosphorylated UKL1 has a molecular weight of 140 kDa, thus the 
lower band was considered phosphorylated ULK1 (Ser317). The molecular weight of total 
ULK1 is according to the manufacturer 150 kDa. Additional effort was made to improve the 
separation of the proteins. The conditions of separating the proteins was changed from 75 
minutes in room temperature (200 V) to 40 minutes in room temperature (200 V), and then 
placed on ice for 75 minutes (180 V). This method gave better separation of the bands (figure 
3.10B), even though unspecific bindings still persisted.    
 
Figure 3.10: Detection of phosphorylated ULK1 (Ser317). A) Two bands between 120-220 kDa 
were detected. Separation of the proteins was performed in room temperature for 75 minutes (200 V). 
B) Separation of the proteins was performed 40 minutes in room temperature (200 V) and 75 minutes 
placed cold (180 V).   
 
As three different blocking methods did not reduce the unspecific bindings, we speculated 
whether the antibody dilution could be improved. The primary antibody towards 
phosphorylated ULK1 (Ser317) was diluted 1:1000 in the initial experiments according to the 
manufacturers recommendation, but was subsequently changed to 1:500. To check if the 
secondary antibody was causing unspecific bindings, a blot was re-probed with a fluorescent 
secondary antibody. Unspecific bindings still occurred with a fluorescent secondary antibody, 
and two bands between 120 and 220 kDa were detected with both HRP-probed and 
fluorescent antibody (figure 3.11).  
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Figure 3.11: Detection of phosphorylated ULK1 with HRP (upper panel) and fluorescent (lower 
panel) secondary antibody.  
 
Another modification which was done to improve the method was to change the lysis buffer. 
Phosphorylated proteins are dephosphorylated by phosphatases, and the concentration of 
phosphatase inhibitors (PIC2 and PIC3) was thus increased.  
AMPK may phosphorylate ULK1 at several residues, including Ser317 and Ser555. A 
antibody specific for ULK1 phosphorylated at Ser555 was used in addition to the antibody 
specific for Ser317. A slight increase in the level of phosphorylated ULK1 (Ser317) was 
observed in AGS-Gr cells (figure 3.12A). Examination of ULK1 with the antibody specific 
for Ser555 also detected a band at 140 kDa. The increase of phosphorylated ULK1 seen by 
use of this antibody peaked after 15 minutes, and then decreased (figure 3.12A). In MKN45, 
the level of phosphorylated ULK1 (Ser317) peaked after 10 minutes and then slowly 
decreased. A pronounced increase of phosphorylated ULK1 (Ser555) was not observed. These 
results indicate that gastrin treatment induces phosphorylation of ULK1 in AGS-Gr and 
MKN45 cells. All together, gastrin mediated phosphorylation of the signalling cascade LKB1-
AMPK-ULK1 suggest a role of gastrin in regulation of autophagy.  
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Figure 3.12: Gastrin mediated phosphorylation of ULK1. Serum-starved cells were treated with 
gastrin (10 nM). Phosphorylated ULK1 (Ser317, Ser555) were detected by Western blot. A) AGS-Gr 
cells. B) MKN45 cells.   
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3.6 Inhibition of autophagy reduces the survival effect of gastrin 
 
Gastrin has previously been shown to induce proliferation via anti-apoptotic/survival 
signalling pathways in vitro [30, 31] and we speculated whether the gastrin mediated increase 
of autophagy was part of this survival effect. To investigate this, we induced cellular stress by 
cisplatin treatment, and investigated whether gastrin induced autophagy would influence the 
survival of the cells. XTT experiments were performed with AGS-Gr cells treated with 
cisplatin or cisplatin together with gastrin. Addition of cisplatin causes DNA damage and 
induction of reactive oxygen species (ROS) in the cells, resulting in cellular stress and 
inhibition of cell division.  
Initially, cisplatin was added in various concentrations (7.5, 15, 30, 60 and 90 µM), and the 
experiment was terminated after 6, 24 and 48 hours of cisplatin stimulation. In unstimulated 
and gastrin treated cells, the anti-apoptotic effect of gastrin was significant after 48 hours of 
treatment (figure 3.13A, 3.14A, 3.15A,C). After 6 hours there was no significant difference in 
cell viability between cells treated with cisplatin alone or cells treated with cisplatin together 
with gastrin (figure 3.13B). Cells treated with 15 µM cisplatin together with gastrin showed 
better viability compared to cisplatin-treated cells alone after 24 hours (figure 3.13C). After 
48 hours, cells treated with gastrin and cisplatin showed significantly higher viability than 
cells treated with cisplatin alone (figure 3.13D). Taken together, these results indicate that the 
apoptotic effect of cisplatin is reduced with gastrin treatment.  
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Figure 3.13: Gastrin reduces the apoptotic effect of cisplatin in AGS-Gr cells.  Cells were treated 
with gastrin (10 nM) for 2 hours, and then treated with cisplatin. A) Unstimulated and gastrin-treated 
cells. B-D) Gastrin and cisplatin treated cells. The statistical significance between unstimulated vs. 
gastrin treated cells, and cisplatin and gastrin treatment vs cisplatin treatment was found by two-tailed 
student T-test. *: P-value ≤ 0.05. **: P-value ≤ 0.01. ***: P-value ≤ 0.001. Graphs show mean value 
and standard deviation.  
 
In the initial experiment, high doses (15-90 µM) of cisplatin showed relatively low cell 
viability after 48 hours, and it was of interest to examine whether the effect of gastrin was still 
significant with lower concentrations of cisplatin. Cells were therefore treated with 1.0, 4.0, 
7.5 and 15 µM of cisplatin and the experiment was terminated after 24, 48 and 72 hours 
(figure 3.14B-D). The cell viability was also significantly higher in cells treated with 15 µM 
cisplatin together with gastrin, compared to cisplatin alone after 24 hours (figure 3.14B). The 
cell viability increased significantly when stimulating cisplatin together with gastrin after 48 
and 72 hours treatment (figure 3.14C,D). These results indicate that the anti-apoptotic effect 
of gastrin is best shown after 48 hours treatment and that the apoptotic effect caused by 
cisplatin is partly reduced with gastrin treatment. 
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Figure 3.14: Gastrin reduces the apoptotic effect of cisplatin in AGS-Gr cells.  Cells were pre-
treated with 10 nM gastrin for 2 hours, and treated with the cisplatin. A) Unstimulated and gastrin-
treated cells. B-D) Gastrin and cisplatin treated cells. The statistical significance between unstimulated 
vs. gastrin stimulated, and Cisplatin and Gastrin vs Cisplatin was found by two-tailed student T-test.  
*: P-value ≤ 0.05. **: P-value ≤ 0.01. ***: P-value ≤ 0.001. Graphs show mean value and standard 
deviation. 
 
Further, we hypothesized that induction of autophagy could be one of the mechanisms of the 
survival effect of gastrin. Therefore we blocked autophagy by hydroxy-chloroquine (HCQ) 
(10 μM) in cells treated with gastrin and cisplatin for 24 hours (figure 3.15B) and 12 hours 
(figure 3.15D) and terminated the experiments after 48 and 36 hours, respectively. HCQ 
inhibits the acidification of lysosomes and prevents the fusion of lysosomes and 
autophagosomes. The results showed that blocking of autophagy in cells treated with gastrin 
displayed decreased viability compared to cells treated with gastrin alone (figure 3.15A,C). 
The viability in cells treated with HCQ and cisplatin was also examined (Appendix 2).  
Results showed that cells treated with cisplatin and gastrin showed decreased viability when 
autophagy was blocked for 12 hours (figure 3.15B). To check if blocking of autophagy at an 
earlier time-point would reduce the viability further, HCQ was added for 24 hours and the 
experiment was terminated after 36 hours of cisplatin treatment. The cell viability was 
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significant decreased when comparing gastrin treated cells to unstimulated cells, and the 
reduction in viability was also significant when blocking autophagy (figure 3.15C). Blocking 
of autophagy for 24 hours resulted in further significant reduction in cell viability (figure 
3.15D). Taken together, these results suggest that blocking of autophagy with HCQ partly 
reduces the anti-apoptotic effect of gastrin, and sensitized cells to cisplatin- induced cell death.  
 
 
Figure 3.15: Blocking of autophagy reduces the survival effect of gastrin in AGS-Gr cells.  Cells 
were treated with 10 nM gastrin for 2 hours, and then treated with cisplatin for 48 hours (A-B) and 36 
hours (C-D). A, B) Autophagy was blocked for 12 hours. Results are representative of two 
independent experiments. C, D) Autophagy was blocked for 24 hours. Results are from one 
experiment. The statistical significance between unstimulated cells vs. gastrin treated cells, and 
cisplatin, gastrin and HCQ treatment vs cisplatin and gastrin treatment was found by two-tailed 
student T-test. *: P-value ≤ 0.05. **: P-value ≤ 0.01. ***: P-value ≤ 0.001. Graphs show mean value 
and standard deviation. 
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4. Discussion 
 
Understanding the molecular mechanisms of gastrin may contribute to a better understanding 
of gastrin in pathological conditions. In this thesis, gastrin-mediated autophagy in two human 
gastric adenocarcinoma cell lines has been examined; AGS-Gr, which overexpresses the 
CCK2 receptor and MKN45 which expresses the receptor endogenously. The levels of the 
autophagy markers LC3-II and p62 were shown to increase by gastrin treatment, and the 
signaling pathway LKB1 – AMPK – ULK1, known to induce autophagy, was activated by 
gastrin. Taken together, our results suggest a role for gastrin in regulating autophagy in AGS-
Gr and MKN45 cells. Gastrin showed a survival effect in cisplatin-treated cells, and blocking 
of autophagy reduced the survival effect of gastrin.  
In this study we show for the first time that gastrin, which exerts growth-promoting effects on 
AGS-Gr and MKN45 cells, induces autophagy in these gastric adenocarcinoma cell lines. 
Transforming growth factor beta (TGF-β) has been shown to induce autophagy in renal 
tubular epithelial cells [68], hepatocellular carcinoma cells and in mammary carcinoma cells 
[69]. To date, few studies have uncovered hormone or growth factor regulation of autophagy.  
Since gastrin is shown to have survival effects, we speculated that gastrin-mediated autophagy 
could have a cytoprotective role in our cell line system. By performing XTT experiments, we 
showed that cells treated with cisplatin and gastrin showed better viability than cells treated 
with cisplatin alone. Cisplatin is an anti-cancer drug used in a variety of malignancies, 
including gastric cancer [70]. Its cytotoxic mode of action is induction of DNA damage 
wherein DNA adducts induce signaling cascades that result in apoptosis. Cisplatin commonly 
works well initially, but treatment with cisplatin often results in resistance [71, 72]. In our 
experiments we show that gastrin partially counteracts the apoptotic effect of cisplatin, and 
that blocking of autophagy reduced the survival effect of gastrin. Harhaji-Trajkovic et al. [73] 
showed that cisplatin induced both phosphorylation of AMPK and autophagy in glioma cell 
lines. Inhibition of autophagy at both early and late stages increased cisplatin-induced 
apoptosis, and siRNA towards AMPK impaired autophagy and also sensitized cells to 
apoptosis [73]. Liang et al. [74] found that 5-Fluorouracil (5-FU) induced autophagy in a 
gallbladder carcinoma cell line, and that blocking of autophagy sensitized the cells to 5-FU-
induced apoptosis. They also showed that siRNA towards Atg5 and Atg7 induced 5-FU-
mediated apoptosis. Similar results were found in a lung cancer cell line where Atg5 was 
knocked down with siRNA and blocking of autophagy enhanced the 5-FU induced apoptosis 
38 
 
[75]. Furthermore, blocking of autophagy has been shown to sensitize gastric cancer cells to 
oxaliplatin-induced apoptosis in a study by Xu et al. [76]. Kim et al. [77] showed that 
cisplatin treatment induced phosphorylation of AMPK in AGS cells, and that pharmacological 
inhibition of AMPK and siRNA towards AMPK sensitized the cells to cisplatin-induced 
apoptosis [77]. These results suggest that AMPK and autophagy contribute to general 
chemotherapy resistance and act in a cytoprotective manner in response to several anti-cancer 
drugs. A study by Li et al. [78] showed that blocking of autophagy induced 5-FU-mediated 
apoptosis in human colon cancer, both in vitro and in an in vivo xenograft model. The studies 
are consistent with our results showing that blocking of autophagy enhanced cisplatin-
mediated apoptosis in AGS-Gr cells.   
In a study by Yu et al. [79], a cisplatin-resistant ovarian cancer cell line showed increased 
expression of p62, and knock-down of p62 in the cisplatin-resistant cells re-sensitized the 
cells to cisplatin-induced apoptosis [79]. These findings also indicate a protective role for 
autophagy in cisplatin treatment. However, conflicting results have been reported. Yang et al. 
found that cisplatin-induced autophagy enhanced apoptosis in bladder cancer cells [80]. In 
cisplatin-resistant ovarian cancer cells Feng et al. [81] reported that a combined treatment of 
cisplatin and Dihydroartemisinin (DHA) sensitized cells to apoptosis, and that autophagy was 
induced by DHA [81]. However, blocking of autophagy in the resistant cells did not affect 
cell viability. 
In an in vivo study by Kang et al. [82], immunohistochemistry showed that patients with low 
expression of phosphorylated AMPK in the tumor had higher relapse-free survival than 
patients with high expression of phosphorylated AMPK. The results were from 74 patients 
suffering from gastric adenocarcinoma who had undergone resection and adjuvant cisplatin 
treatment [82]. Zheng et al. [83], on the other hand, reported that phosphorylated AMPK was 
down-regulated in patients with hepatocellular carcinoma, and that low expression of 
phosphorylated AMPK was associated with poor prognosis. Consistent with these results, 
William et al. [84] found high expression of AMPK in non-small cell lung cancer (NSCLC) to 
be associated with better prognosis. Choi et al. found that negative expression of LC3-II in 
vivo was associated with poor survival in patients with colorectal adenocarcinoma [85]. LC3-
II was shown to have high expression in gastrointestinal cancers, including gastric 
adenocarcinoma in addition to esophageal and colorectal cancer, compared to noncancerous 
epithelial cells [86]. Altogether, these conflicting results emphasise the dual and complex role 
of autophagy in cancer and apoptosis. Whether autophagy acts in a cytotoxic or cytoprotective 
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manner is likely context dependent, and may also be dependent on stimuli. In our cell line 
system, gastrin induced both phosphorylation of AMPK and autophagy. In addition, gastrin 
reduced cisplatin-mediated apoptosis in AGS-Gr, while blocking of autophagy sensitized cells 
to cisplatin-induced apoptosis (figure 3.15). Our results suggest a role of gastrin-mediated 
autophagy as a protective factor in cisplatin resistance in AGS-Gr.   
When cultivating MKN45 cells in HANKS no increase of LC3-II and p62 was observed. 
HANKS medium lacks amino acids, and cultivation in HANKS should thus be a potent 
inducer of autophagy and, in turn, increase the autophagic flux. The term autophagic flux 
denotes the whole process of autophagy, wherein autophagosomes are formed, fuses with the 
lysosome and is degraded [41]. Kim et al. [36] showed that amino acid-starvation induced 
activation of ULK1 in MEF cells, but ULK1 was not phosphorylated at the Ser317 residue 
known to be phosphorylated by AMPK. Glucose starvation, on the other hand, resulted in 
phosphorylation of ULK1 (Ser317). In cells with AMPK mutant, amino acid starvation could 
still stimulate ULK1 activation, even though the overall ULK1 activation was reduced in the 
cells. ULK1 was not activated in glucose-starved cells expressing the AMPK mutant [36]. 
These results indicate that amino acid-starvation may activate autophagy in an AMPK-
independent manner. In contrast, Sato et al. [87] demonstrated that amino acid-starvation in 
colorectal cancer cell lines induced the expression of LC3-II and increased phosphorylation of 
AMPK. These results indicate that it is likely cell-specific whether amino acid-starvation 
activates AMPK and thus initiates autophagy. In our study we have shown that AMPK is 
activated in serum-starved cells upon gastrin treatment, but whether cultivation in HANKS 
activates AMPK was not examined. The basal autophagic flux induced by amino acid 
starvation might have been so high that there was no additional effect of gastrin in MKN45 
cultivated in HANKS. 
After finishing the laboratory work for this thesis, the gastrin-mediated increase in autophagy 
was further demonstrated by combined knock-down of Atg5 and Atg7 by siRNA in MKN45 
cells. Some more experiments will be conducted to further show the gastrin-mediated increase 
of autophagy. Since ULK1 is a direct activator of autophagy, knock-down of ULK1 could be 
performed to further show that gastrin mediates autophagy in the cell lines. We could also 
examine ULK1 phosphorylated by mTOR (Ser757) upon gastrin treatment.  
To further establish whether gastrin activates the LKB1 – AMPK – ULK1 pathway to initiate 
autophagy, additional experiments could be performed. Knock-down of LKB1 by siRNA 
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could have been used to examine whether LKB1 knock-down would reduce or cancel the 
gastrin-mediated increase in LC3-II and p62. LKB1 resides in the nucleus, but translocates to 
the cytoplasm when phosphorylated (Ser428) and activated, and LKB1 may then activate 
AMPK [38]. With this in mind, it would be interesting to examine whether gastrin treatment 
would mediate the translocation of LKB1 from the nucleus to the cytoplasm.  
Hypergastrinemia is considered to be a risk factor for gastric malignancy, but the role of 
gastrin in gastric cancer has been debated for decades. We have shown for the first time that 
gastrin induces autophagy, likely through activation of LKB1, AMPK and ULK1. Conflicting 
results regarding the role of autophagy in cancer suggest that whether autophagy acts in a 
cytoprotective or cytotoxic manner is likely context dependent. In this study we have shown 
that gastrin-induced autophagy in gastric adenocarcinoma cells likely exerts a protective 
effect in response to chemotherapy. These results may contribute to a better understanding of 
the role of gastrin in gastric cancer. Blocking of autophagy may be a potential target for 
sensitizing gastric cancer cells to apoptosis in response to chemotherapy.  
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Appendix 1 
 
Urea lysis buffer 
The extraction buffer was produced by dissolving urea (2.4 g) in dH2O (3 ml, 25ºC), and then 
adding additional dH2O until the total volume was 5 ml. 25 μl Triton x100 (VWR) was added. 
Aliquots (410 μl) were stored at -20ºC. When the lysis buffer was to be used, DL-
Dithiothreitol solution (DTT), protease (PI) and phosphatase (PIC) inhibitors were added to 
the extraction buffer. For details, see table A1. 
Table A1: Urea lysis buffer 
 Concentration Concentration in buffer Volume 
Extraction buffer   410 μl 
DTT (Sigma) 1 M 0.1 M 50 μl 
PI (Roche) 25X 1X 20 μl 
PIC2 (Sigma) 250X 5X 10 μl 
PIC3(Sigma) 250X 5X 10 μl 
 
TBST 
 Table A2: 20X TBS Stock solution 
1 M Trizma Base (Sigma) 122 g 
18% NaCl (Merck) 180 g 
Tween 20 (VWR) 1 ml 
dH2O Add until 1000 ml 
 
The pH of the buffer was adjusted to 7.6.  TBST working solution was made by diluting the 
20X TBS stock solution 1:20 in dH2O and adding 0.1% Tween 20.  
 
Transfer buffer 
Table A3: Transfer buffer  
20X NuPAGE Transfer buffer (Novex) 50 ml 
NuPAGE Antioxidant (Invitrogen) 1 ml 
10% Methanol  100 ml 
dH2O 849 ml 
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Ponceau staining 
Table A4: Ponceau staining 
Ponceau 1 g 
Acetic acid 50 ml 
dH2O Add until 1000 ml 
 
  
48 
 
Appendix 2 
 
When blocking autophagy in cisplatin-treated cells, the viability significantly decreased 
compared to cisplatin treatment alone (figure A1). Results shown are from cells treated with 
7.5 μM cisplatin for 48 hours. Similar results were observed in cells treated with other 
concentrations (1.0 and 4.0 μM) of cisplatin. In cells treated with cisplatin in presence of 
gastrin, the viability was higher than in cells treated with cisplatin in absence of gastrin.  
 
 
Figure A1:  Cells were pre-treated with 10 nM gastrin for 2 hours, and treated with cisplatin (7.5μM) 
for 48 hours. HCQ (10 µM) was added after 36 hours. The statistical significance was found by 
student T-test. *: P-value ≤ 0.05. **: P-value ≤ 0.01. ***: P-value ≤ 0.001. Graphs show mean value 
and standard deviation. 
 
